Onsenal withdrawn

Pfizer has withdrawn Onsenal (celecoxib) after concluding that it is unable to meet the conditions of the product’s marketing authorisation.

Onsenal was launched in June 2010 as an adjunct to surgery and further endoscopic surveillance in the treatment of familial adenomatous polyposis. Approval for this rare condition was granted on the basis of data showing a reduction in polyp number following treatment with the COX-2 inhibitor. At the time of approval the EMA requested that the manufacturer provide post-approval data on clinically relevant efficacy outcomes. The long-term placebo-controlled Children’s International Polyposis trial was initiated in response to this request, but the trial has progressed too slowly to meet its enrolment goals. Celecoxib remains available as Celebrex for osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.

Further Information: Pfizer

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New antibiotic guidance for diabetic foot infection

New antibiotic guidance for diabetic foot infection

NICE has updated its guidance on the prevention and...

Drug shortages - live tracker

Drug shortages - live tracker

Added: co-fluampicil.
Use our constantly updated...

Further drug shortages prompt advice to consider unlicensed alternatives

Further drug shortages prompt advice to consider unlicensed alternatives

Prescribers are being advised to prioritise supplies...

Vaping still safer than smoking, say health bosses after report of severe lung injury